Menu
Currency
GWAS Study

Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment.

Clark SL, Souza RP, Adkins DE et al.

23241943 PubMed ID
GWAS Study Type
738 Participants
42 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

CS
Clark SL
SR
Souza RP
AD
Adkins DE
AK
Aberg K
BJ
Bukszár J
MJ
McClay JL
SP
Sullivan PF
VD
van den Oord EJ
Chapter II

Abstract

Summary of the research findings

Objective: To examine the unique and congruent findings between multiple raters in a genome-wide association study (GWAS) in the context of understanding individual differences in treatment response during antipsychotic therapy for schizophrenia.

Up to 421 European ancestry Schizophrenia cases, up to 214 African American individuals, up to 103 individuals

Chapter III

Study Statistics

Key metrics and study information

738
Total Participants
GWAS
Study Type
No
Replicated
European, African American or Afro-Caribbean
Ancestry
U.S.
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.